Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Aclaris Therapeutics (ACRS) reported a Q4 loss of $0.10 per share, which was better than the Zacks Consensus Estimate of a $0.32 loss. This is an improvement from the $0.30 loss per share reported a year ago.
February 27, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclaris Therapeutics reported a Q4 loss of $0.10 per share, surpassing the Zacks Consensus Estimate of a $0.32 loss. This marks an improvement from the previous year's $0.30 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to positively impact Aclaris Therapeutics' stock price in the short term. The improvement from the previous year's loss also adds to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100